TY - JOUR
T1 - Wegener's granulomatosis
T2 - Prospective clinical and therapeutic experience with 85 patients for 21 years
AU - Fauci, A. S.
AU - Haynes, B. F.
AU - Katz, P.
AU - Wolff, S. M.
PY - 1983/1/1
Y1 - 1983/1/1
N2 - Eighty-five patients with Wegener's granulomatosis were studied for 21 years at the National Institutes of Health. Patients were treated with a protocol consisting of cyclophosphamide, 2 mg/kg body weight·d, together with prednisone, 1 mg/kg bodyweight ·d, followed by conversion of the prednisone to an alternate-day regimen. Complete remissions were achieved in 79 of 85 patients (93%). The mean duration of remission for living patients was 48.2 (± 3.6) months. Twenty-three patients are off all therapy for a mean duration of 35.3 (± 6.3) months without therapy. This study provides a prospective experience with Wegener's granulomatosis and shows that long-term remissions can be induced and maintained in an extremely high number of patients by the combination of daily cyclophosphamide and alternate-day prednisone therapy.
AB - Eighty-five patients with Wegener's granulomatosis were studied for 21 years at the National Institutes of Health. Patients were treated with a protocol consisting of cyclophosphamide, 2 mg/kg body weight·d, together with prednisone, 1 mg/kg bodyweight ·d, followed by conversion of the prednisone to an alternate-day regimen. Complete remissions were achieved in 79 of 85 patients (93%). The mean duration of remission for living patients was 48.2 (± 3.6) months. Twenty-three patients are off all therapy for a mean duration of 35.3 (± 6.3) months without therapy. This study provides a prospective experience with Wegener's granulomatosis and shows that long-term remissions can be induced and maintained in an extremely high number of patients by the combination of daily cyclophosphamide and alternate-day prednisone therapy.
UR - http://www.scopus.com/inward/record.url?scp=0020656868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020656868&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-98-1-76
DO - 10.7326/0003-4819-98-1-76
M3 - Review article
C2 - 6336643
AN - SCOPUS:0020656868
VL - 98
SP - 76
EP - 85
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
SN - 0003-4819
IS - 1
ER -